EA202192117A1 - Способ лечения множественной миеломы - Google Patents
Способ лечения множественной миеломыInfo
- Publication number
- EA202192117A1 EA202192117A1 EA202192117A EA202192117A EA202192117A1 EA 202192117 A1 EA202192117 A1 EA 202192117A1 EA 202192117 A EA202192117 A EA 202192117A EA 202192117 A EA202192117 A EA 202192117A EA 202192117 A1 EA202192117 A1 EA 202192117A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- multiple myeloma
- subject
- treatment
- administering
- molecular weight
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 4
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 3
- 150000003384 small molecules Chemical class 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812002P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/019884 WO2020176610A1 (en) | 2019-02-28 | 2020-02-26 | Method for treating a multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192117A1 true EA202192117A1 (ru) | 2021-11-23 |
Family
ID=72238680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192117A EA202192117A1 (ru) | 2019-02-28 | 2020-02-26 | Способ лечения множественной миеломы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220143016A1 (https=) |
| EP (1) | EP3931196A4 (https=) |
| JP (1) | JP2022521801A (https=) |
| CN (1) | CN113710670A (https=) |
| AU (1) | AU2020227748A1 (https=) |
| BR (1) | BR112021016747A2 (https=) |
| CA (1) | CA3131249A1 (https=) |
| EA (1) | EA202192117A1 (https=) |
| IL (1) | IL285800A (https=) |
| MX (1) | MX2021010398A (https=) |
| WO (1) | WO2020176610A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (https=) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| EP2624818B1 (en) * | 2010-10-05 | 2017-04-05 | Fresenius Kabi USA, LLC | Bortezomib formulations stabilised with boric acid |
| NZ746607A (en) * | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| EA034866B1 (ru) * | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
| EP3836932A2 (en) * | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| US20220185795A1 (en) * | 2019-03-11 | 2022-06-16 | Ptc Therapeutics, Inc. | Compound form having enhanced bioavailability and formulations thereof |
-
2020
- 2020-02-26 WO PCT/US2020/019884 patent/WO2020176610A1/en not_active Ceased
- 2020-02-26 CN CN202080030185.4A patent/CN113710670A/zh active Pending
- 2020-02-26 BR BR112021016747-1A patent/BR112021016747A2/pt not_active Application Discontinuation
- 2020-02-26 MX MX2021010398A patent/MX2021010398A/es unknown
- 2020-02-26 US US17/433,106 patent/US20220143016A1/en not_active Abandoned
- 2020-02-26 AU AU2020227748A patent/AU2020227748A1/en not_active Abandoned
- 2020-02-26 EP EP20762789.4A patent/EP3931196A4/en active Pending
- 2020-02-26 JP JP2021550168A patent/JP2022521801A/ja active Pending
- 2020-02-26 EA EA202192117A patent/EA202192117A1/ru unknown
- 2020-02-26 CA CA3131249A patent/CA3131249A1/en active Pending
-
2021
- 2021-08-23 IL IL285800A patent/IL285800A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020227748A1 (en) | 2021-09-16 |
| CN113710670A (zh) | 2021-11-26 |
| BR112021016747A2 (pt) | 2021-10-19 |
| WO2020176610A8 (en) | 2021-08-12 |
| IL285800A (en) | 2021-10-31 |
| EP3931196A4 (en) | 2022-12-14 |
| JP2022521801A (ja) | 2022-04-12 |
| CA3131249A1 (en) | 2020-09-03 |
| WO2020176610A1 (en) | 2020-09-03 |
| EP3931196A1 (en) | 2022-01-05 |
| MX2021010398A (es) | 2022-01-18 |
| US20220143016A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
| GEAP202315703A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| GEAP202215479A (en) | Magl inhibitors | |
| EA202190581A1 (ru) | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a | |
| EA201890768A3 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| BR112015013123A2 (pt) | inibidores de beta-lactamase | |
| MX389999B (es) | Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| EA201792287A1 (ru) | Способы лечения рака | |
| MX2022007626A (es) | Combinaciones. | |
| CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MX389692B (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2016002308A (es) | Tratamiento del mieloma multiple. | |
| MY183483A (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof |